





Construct A (only the relevant heavy chain sequences shown below).




Construct B (F(ab')₂; mAb variable chain sequences not shown).



Construct C (Fab; mAb variable chain sequences not shown).



Construct D (Fab w/C_K/λ/V_H linked; mAb heavy chain constant domain, mAb light chain variable domain and gp39 sequences not shown).



Construct E (Fv).



Fig. 1

Proposed TAA-specific mAb/gp39 immunotherapeutic fusion proteins

2/2




Fig. 2

Anti-tumor immune response induction by a TAA
specific mAb-gp39 chimeric protein